2 recruiting, 1 suspended. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Suspended 1 |
| Phase 1 | 1 | Suspended 1 |
Follow Chronic Neuropathic Pain: new trials by email Literature Review of Chronic Neuropathic Pain trials Research Report on Chronic Neuropathic Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial 3,4-Methylenedioxymethamphetamine, Methylphenidate - Chronic Neuropathic Pain | Phase 2 | Recruiting | Unity Health Toronto | 50 | 2026-01-30 | 2026-07-29 |
| Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) ST-503, Sham (No Treatment) - Chronic Neuropathic Pain | Phase 1 / Phase 2 | Suspended | Sangamo Therapeutics | 27 | 2025-12-04 | 2026-11-03 |
| Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN Psilocybin, Active Placebo - Chronic Neuropathic Pain, Pain Management | Phase 2 | Recruiting | Unity Health Toronto | 30 | 2025-03-05 | 2025-03-30 |
Agnosia (1) · Chronic Pain (1) · Neuralgia (1) · Small Fiber Neuropathy (1)
Nervous System Diseases (2) · Neuromuscular Diseases (2) · Peripheral Nervous System Diseases (2) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pain (1) · Pathological Conditions, Signs and Symptoms (1) · Perceptual Disorders (1) · Signs and Symptoms (1)
Methylphenidate (1) · N-Methyl-3,4-methylenedioxyamphetamine (1) · Psilocybin (1) · Psychotherapy (1) · salicylhydroxamic acid (1)
Unity Health Toronto (2) · Sangamo Therapeutics (1)
Canada (2) · United States (1)
PMID 21674151, PMID 24550805, PMID 27578767, PMID 28704354, PMID 29577509, PMID 29764303, PMID 32371500, PMID 34867525, PMID 35001856, PMID 36044208, PMID 36532184